0

Close
 
Upcoming Allied Market Research
2023
Avian Influenza Vaccine Market

Avian Influenza Vaccine Market

by Strain (H5, H7, H9) and by Application (Chicken, Turkey, Duck, Goose): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare
Report Code: A12464
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Avian Influenza Vaccine Market

Request Now !

Avian Influenza Vaccine Market Outlook 2030:

Avian influenza is a disease caused by bird flu type A virus, which is found in aquatic birds and subsequently causes infection in domestic poultry. The virus was first detected in China. The Asian H5N1 version was detected in the subsequent year during an outbreak in Hong Kong and since then has spread across Europe, Asia, North & South America, Africa, and the Middle East. Avian influenza can be divided into highly pathogenic and low pathogenic based on its molecular structure. Depending on the strains, the virus is divided into H5N1, H7N3, H7N7, H7N9, and H9N2.  Additionally, virus of type A of subtype H5N1 is considered to be the most pathogenic avian influenza virus currently under research. Avian influenza is known to cause infection in humans through nose and mouth inhalation. The classification of avian influenza vaccines include H5 avian influenza vaccine, H7 avian influenza vaccine, and H9 avian influenza vaccine. Among manufacturing nations, China stands out as the largest supplier of avian influenza vaccines, followed by the U.S. and European Union.

Avian Influenza Vaccine Market Scope and Structure Analysis

COVID-19 Impact Analysis

Impact of COVID-19 on Animal Influenza Vaccine Market

The coronavirus pandemic is having a huge impact on businesses and has already caused an unprecedented collapse of economic activities. The COVID-19 impact is straining the healthcare systems globally.

The COVID-19 cases are increasingly due to direct or indirect contact between humans. There has been no evidence or confirmation that animals can spread COVID-19 to humans. The myth animals can spread the virus to humans has increased the number of abandoned pets. Furthermore, COVID-19 has weakened the supply chain and has created shortage of animal health products such as nutritional feed as well as vaccines globally. The animal health industry has been impacted largely as many manufacturers in the animal health industry are left with a significantly reduced workforce. Also, implementation of stringent government policies such as restrictions of import of raw materials from China is expected to hamper the growth of the animal health market.

Healthcare facilities are stocking up the animal-related health products, considering the high demand. This is expected to further create financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.

Top Impacting Factors

  • The growing incidence of the poultry mortality due to avian influenza coupled with a desire to consumer more poultry is paving the way for enhanced avian influenza vaccine development programs.
  • Emergence of regional vaccine developers in regions such as China and India with higher consumer base provide an impetus to the market in line for an exponential growth. These developers are in line to purchase cold storage facilities and open new research centers to boost vaccine manufacturing capabilities.
  • Public and private sector investments and increased strategic collaborations act as the key drivers of avian influenza vaccine market growth.
  • Underdeveloped veterinary infrastructure consisting of genome facilities, vaccine design, and immunization facilities, and R&D expertise in third world economies hampers the vaccine market growth.

Key Market Trends

  • The Asia-Pacific countries, including China, India, and South Korea along with Israel are witnessing the highest outbreak of avian influenza virus. This is being followed by rapid expansion in supply chain efficiencies coupled with supportive government initiatives and increase in R&D infrastructure.
  • Just as the U.S. has been the leading COVID-19 vaccine developer, it finds its place as the fastest growing avian influenza market, owing to factors such as rise in awareness regarding animal welfare and animal & veterinary vaccine research-related activities across the continent.
  • Rapid spread of avian influenza in an already vaccinated population such as India has resulted in both antigenic and genetic changes in the structure of the virus.
  • Recent outbreak of H5N8 strain of the virus has established the fact that it came from different lineage of virus, different from the current virus spread across Europe and Asia.

Key Benefits of the Report

  • This study presents the analytical depiction of the avian influenza vaccine industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Avian Influenza Vaccine Market Report

  • Which are the leading players active in the avian influenza vaccine market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the avian influenza vaccine market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is avian influenza vaccine?
  • What is the avian influenza vaccine market prediction in the future?
  • What are the current trends and predicted trends?

 Avian Influenza Vaccine Market Report Highlights

Aspects Details
By Strain
  • H5
  • H7
  • H9
By Application
  • Chicken
  • Turkey
  • Duck
  • Goose
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Medion, PT Japfa Comfeed Indonesia Tbk, Zoetis, Yebio Bioengineering Co. Ltd., Chengdu Technabank Biological Products Co. Ltd., Fatro S.P.A., Tianjin Ringpu Biotechnology Co. Ltd., Merck Animal Health, Ceva, Cavac
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: AVIAN INFLUENZA VACCINE MARKET, BY STRAIN

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Strain

    • 4.2. H5

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. H7

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. H9

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: AVIAN INFLUENZA VACCINE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Chicken

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Turkey

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Duck

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Goose

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: AVIAN INFLUENZA VACCINE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Strain

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Avian Influenza Vaccine Market

        • 6.2.5.1. Market Size and Forecast, By Strain
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Avian Influenza Vaccine Market

        • 6.2.6.1. Market Size and Forecast, By Strain
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Avian Influenza Vaccine Market

        • 6.2.7.1. Market Size and Forecast, By Strain
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Strain

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Avian Influenza Vaccine Market

        • 6.3.5.1. Market Size and Forecast, By Strain
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Avian Influenza Vaccine Market

        • 6.3.6.1. Market Size and Forecast, By Strain
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Avian Influenza Vaccine Market

        • 6.3.7.1. Market Size and Forecast, By Strain
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Avian Influenza Vaccine Market

        • 6.3.8.1. Market Size and Forecast, By Strain
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Avian Influenza Vaccine Market

        • 6.3.9.1. Market Size and Forecast, By Strain
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Avian Influenza Vaccine Market

        • 6.3.10.1. Market Size and Forecast, By Strain
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Avian Influenza Vaccine Market

        • 6.3.11.1. Market Size and Forecast, By Strain
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Strain

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Avian Influenza Vaccine Market

        • 6.4.5.1. Market Size and Forecast, By Strain
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Avian Influenza Vaccine Market

        • 6.4.6.1. Market Size and Forecast, By Strain
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Avian Influenza Vaccine Market

        • 6.4.7.1. Market Size and Forecast, By Strain
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Avian Influenza Vaccine Market

        • 6.4.8.1. Market Size and Forecast, By Strain
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Avian Influenza Vaccine Market

        • 6.4.9.1. Market Size and Forecast, By Strain
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Avian Influenza Vaccine Market

        • 6.4.10.1. Market Size and Forecast, By Strain
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Avian Influenza Vaccine Market

        • 6.4.11.1. Market Size and Forecast, By Strain
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Avian Influenza Vaccine Market

        • 6.4.12.1. Market Size and Forecast, By Strain
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Avian Influenza Vaccine Market

        • 6.4.13.1. Market Size and Forecast, By Strain
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Strain

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Avian Influenza Vaccine Market

        • 6.5.5.1. Market Size and Forecast, By Strain
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Avian Influenza Vaccine Market

        • 6.5.6.1. Market Size and Forecast, By Strain
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Avian Influenza Vaccine Market

        • 6.5.7.1. Market Size and Forecast, By Strain
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Avian Influenza Vaccine Market

        • 6.5.8.1. Market Size and Forecast, By Strain
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Avian Influenza Vaccine Market

        • 6.5.9.1. Market Size and Forecast, By Strain
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Avian Influenza Vaccine Market

        • 6.5.10.1. Market Size and Forecast, By Strain
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Ceva

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Yebio Bioengineering Co. Ltd.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Zoetis

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Fatro S.P.A.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Cavac

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Tianjin Ringpu Biotechnology Co. Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. PT Japfa Comfeed Indonesia Tbk

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Chengdu Technabank Biological Products Co. Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Merck Animal Health

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Medion

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL AVIAN INFLUENZA VACCINE MARKET, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR H5, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR H7, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR H9, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL AVIAN INFLUENZA VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR CHICKEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR TURKEY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR DUCK, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL AVIAN INFLUENZA VACCINE MARKET FOR GOOSE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL AVIAN INFLUENZA VACCINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA AVIAN INFLUENZA VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 14. U.S. AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 15. U.S. AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. CANADA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 17. CANADA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE AVIAN INFLUENZA VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. ITALY AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 28. ITALY AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. UK AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 32. UK AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC AVIAN INFLUENZA VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. CHINA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 41. CHINA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. INDIA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 45. INDIA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA AVIAN INFLUENZA VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. UAE AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 68. UAE AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA AVIAN INFLUENZA VACCINE, BY STRAIN, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA AVIAN INFLUENZA VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. CEVA: KEY EXECUTIVES
  • TABLE 74. CEVA: COMPANY SNAPSHOT
  • TABLE 75. CEVA: OPERATING SEGMENTS
  • TABLE 76. CEVA: PRODUCT PORTFOLIO
  • TABLE 77. CEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. YEBIO BIOENGINEERING CO. LTD.: KEY EXECUTIVES
  • TABLE 79. YEBIO BIOENGINEERING CO. LTD.: COMPANY SNAPSHOT
  • TABLE 80. YEBIO BIOENGINEERING CO. LTD.: OPERATING SEGMENTS
  • TABLE 81. YEBIO BIOENGINEERING CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 82. YEBIO BIOENGINEERING CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. ZOETIS: KEY EXECUTIVES
  • TABLE 84. ZOETIS: COMPANY SNAPSHOT
  • TABLE 85. ZOETIS: OPERATING SEGMENTS
  • TABLE 86. ZOETIS: PRODUCT PORTFOLIO
  • TABLE 87. ZOETIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. FATRO S.P.A.: KEY EXECUTIVES
  • TABLE 89. FATRO S.P.A.: COMPANY SNAPSHOT
  • TABLE 90. FATRO S.P.A.: OPERATING SEGMENTS
  • TABLE 91. FATRO S.P.A.: PRODUCT PORTFOLIO
  • TABLE 92. FATRO S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. CAVAC: KEY EXECUTIVES
  • TABLE 94. CAVAC: COMPANY SNAPSHOT
  • TABLE 95. CAVAC: OPERATING SEGMENTS
  • TABLE 96. CAVAC: PRODUCT PORTFOLIO
  • TABLE 97. CAVAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: KEY EXECUTIVES
  • TABLE 99. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: COMPANY SNAPSHOT
  • TABLE 100. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: OPERATING SEGMENTS
  • TABLE 101. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 102. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. PT JAPFA COMFEED INDONESIA TBK: KEY EXECUTIVES
  • TABLE 104. PT JAPFA COMFEED INDONESIA TBK: COMPANY SNAPSHOT
  • TABLE 105. PT JAPFA COMFEED INDONESIA TBK: OPERATING SEGMENTS
  • TABLE 106. PT JAPFA COMFEED INDONESIA TBK: PRODUCT PORTFOLIO
  • TABLE 107. PT JAPFA COMFEED INDONESIA TBK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: KEY EXECUTIVES
  • TABLE 109. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: COMPANY SNAPSHOT
  • TABLE 110. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: OPERATING SEGMENTS
  • TABLE 111. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 112. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. MERCK ANIMAL HEALTH: KEY EXECUTIVES
  • TABLE 114. MERCK ANIMAL HEALTH: COMPANY SNAPSHOT
  • TABLE 115. MERCK ANIMAL HEALTH: OPERATING SEGMENTS
  • TABLE 116. MERCK ANIMAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 117. MERCK ANIMAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. MEDION: KEY EXECUTIVES
  • TABLE 119. MEDION: COMPANY SNAPSHOT
  • TABLE 120. MEDION: OPERATING SEGMENTS
  • TABLE 121. MEDION: PRODUCT PORTFOLIO
  • TABLE 122. MEDION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL AVIAN INFLUENZA VACCINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL AVIAN INFLUENZA VACCINE MARKET
  • FIGURE 3. SEGMENTATION AVIAN INFLUENZA VACCINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN AVIAN INFLUENZA VACCINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAVIAN INFLUENZA VACCINE MARKET
  • FIGURE 11. AVIAN INFLUENZA VACCINE MARKET SEGMENTATION, BY BY STRAIN
  • FIGURE 12. AVIAN INFLUENZA VACCINE MARKET FOR H5, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. AVIAN INFLUENZA VACCINE MARKET FOR H7, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. AVIAN INFLUENZA VACCINE MARKET FOR H9, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. AVIAN INFLUENZA VACCINE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 16. AVIAN INFLUENZA VACCINE MARKET FOR CHICKEN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. AVIAN INFLUENZA VACCINE MARKET FOR TURKEY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. AVIAN INFLUENZA VACCINE MARKET FOR DUCK, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. AVIAN INFLUENZA VACCINE MARKET FOR GOOSE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: AVIAN INFLUENZA VACCINE MARKET
  • FIGURE 26. Top player positioning, 2022
  • FIGURE 27. CEVA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. CEVA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. CEVA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. YEBIO BIOENGINEERING CO. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. YEBIO BIOENGINEERING CO. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. YEBIO BIOENGINEERING CO. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. ZOETIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. ZOETIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. ZOETIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. FATRO S.P.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. FATRO S.P.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. FATRO S.P.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. CAVAC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. CAVAC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. CAVAC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. TIANJIN RINGPU BIOTECHNOLOGY CO. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. PT JAPFA COMFEED INDONESIA TBK: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. PT JAPFA COMFEED INDONESIA TBK: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. PT JAPFA COMFEED INDONESIA TBK: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. CHENGDU TECHNABANK BIOLOGICAL PRODUCTS CO. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. MERCK ANIMAL HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. MERCK ANIMAL HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. MERCK ANIMAL HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. MEDION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. MEDION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. MEDION: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Avian Influenza Vaccine Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers